PMID- 24336504
OWN - NLM
STAT- MEDLINE
DCOM- 20140226
LR  - 20240513
IS  - 1474-1784 (Electronic)
IS  - 1474-1776 (Print)
IS  - 1474-1776 (Linking)
VI  - 13
IP  - 1
DP  - 2014 Jan
TI  - The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and 
      cancer treatment.
PG  - 63-79
LID - 10.1038/nrd4161 [doi]
AB  - The Hippo signalling pathway is an emerging growth control and tumour suppressor 
      pathway that regulates cell proliferation and stem cell functions. Defects in 
      Hippo signalling and hyperactivation of its downstream effectors Yes-associated 
      protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) 
      contribute to the development of cancer, which suggests that pharmacological 
      inhibition of YAP and TAZ activity may be an effective anticancer strategy. 
      Conversely, YAP and TAZ can also have beneficial roles in stimulating tissue 
      repair and regeneration following injury, so their activation may be 
      therapeutically useful in these contexts. A complex network of intracellular and 
      extracellular signalling pathways that modulate YAP and TAZ activities have 
      recently been identified. Here, we review the regulation of the Hippo signalling 
      pathway, its functions in normal homeostasis and disease, and recent progress in 
      the identification of small-molecule pathway modulators.
FAU - Johnson, Randy
AU  - Johnson R
AD  - 1] Department of Biochemistry and Molecular Biology, University of Texas MD 
      Anderson Cancer Center, Houston, Texas 77030, USA. [2] Genes and Development 
      Program, and Cancer Biology Program, Graduate School for Biological Sciences, 
      University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. [3] 
      Program in Developmental Biology, Baylor College of Medicine, Houston, Texas 
      77030, USA.
FAU - Halder, Georg
AU  - Halder G
AD  - VIB Center for the Biology of Disease, KU Leuven Center for Human Genetics, 
      University of Leuven 3000, Belgium.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P50 CA083639/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20131213
PL  - England
TA  - Nat Rev Drug Discov
JT  - Nature reviews. Drug discovery
JID - 101124171
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Hippo Signaling Pathway
MH  - Homeostasis/physiology
MH  - Humans
MH  - Molecular Targeted Therapy/*methods
MH  - Neoplasms/*drug therapy/physiopathology
MH  - Protein Serine-Threonine Kinases/*drug effects/physiology
MH  - Regeneration/*drug effects/physiology
MH  - Signal Transduction/*drug effects/physiology
PMC - PMC4167640
MID - NIHMS622520
EDAT- 2013/12/18 06:00
MHDA- 2014/02/27 06:00
PMCR- 2014/09/18
CRDT- 2013/12/17 06:00
PHST- 2013/12/17 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2014/02/27 06:00 [medline]
PHST- 2014/09/18 00:00 [pmc-release]
AID - nrd4161 [pii]
AID - 10.1038/nrd4161 [doi]
PST - ppublish
SO  - Nat Rev Drug Discov. 2014 Jan;13(1):63-79. doi: 10.1038/nrd4161. Epub 2013 Dec 
      13.